{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009350","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.913648+00:00","generated_at":"2026-06-25T21:13:22.045076+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenaya Q1 net loss $31.1M; TN-201 gets EU orphan designation, IND filings on track","bullets":["Cash, equivalents and marketable securities of $213.5M at March 31; runway into H2 2023.","Net loss of $31.1M ($0.75/sh) for Q1 2022; R&D expense $24.2M, G&A $7.0M.","TN-201 received EU Orphan Medicinal Product designation for MYBPC3 HCM; IND expected H2 2022.","Preclinical TN-401 data at Heart Rhythm 2022 showed restored heart function, reduced arrhythmia, increased survival; IND expected 2023.","cGMP manufacturing facility in Union City expected operational H1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009350","json":"https://secwatch.observer/filing/0000950170-22-009350.json","markdown":"https://secwatch.observer/filing/0000950170-22-009350.md","text":"https://secwatch.observer/filing/0000950170-22-009350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022009350/0000950170-22-009350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022009350/tnya-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:13:22.045076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}